Smithfield Trust Co. reduced its stake in shares of Shire PLC (NASDAQ:SHPG) by 3.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 851 shares of the biopharmaceutical company’s stock after selling 27 shares during the period. Smithfield Trust Co.’s holdings in Shire PLC were worth $140,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in SHPG. Duff & Phelps Investment Management Co. raised its stake in Shire PLC by 14.9% in the first quarter. Duff & Phelps Investment Management Co. now owns 34,473 shares of the biopharmaceutical company’s stock valued at $6,004,000 after buying an additional 4,478 shares in the last quarter. Gateway Investment Advisers LLC raised its stake in shares of Shire PLC by 17.7% in the first quarter. Gateway Investment Advisers LLC now owns 29,806 shares of the biopharmaceutical company’s stock worth $5,193,000 after buying an additional 4,488 shares during the period. Cohen Capital Management Inc. purchased a new stake in shares of Shire PLC during the first quarter worth about $155,000. Pinnacle Bank purchased a new stake in shares of Shire PLC during the first quarter worth about $101,000. Finally, Heritage Investors Management Corp raised its stake in shares of Shire PLC by 11.8% in the first quarter. Heritage Investors Management Corp now owns 21,793 shares of the biopharmaceutical company’s stock worth $3,797,000 after buying an additional 2,295 shares during the period. Institutional investors and hedge funds own 20.22% of the company’s stock.
Shire PLC (NASDAQ:SHPG) traded down 1.62% during mid-day trading on Friday, hitting $145.55. 1,456,564 shares of the company’s stock were exchanged. Shire PLC has a 52 week low of $144.18 and a 52 week high of $209.22. The firm has a 50 day moving average of $160.70 and a 200 day moving average of $171.91.
The company also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be given a dividend of $0.1527 per share. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s payout ratio is 40.63%.
SHPG has been the topic of a number of analyst reports. Piper Jaffray Companies set a $159.00 target price on shares of Shire PLC and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Zacks Investment Research lowered shares of Shire PLC from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Sanford C. Bernstein lowered shares of Shire PLC from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $209.22 to $161.09 in a report on Thursday, May 25th. BidaskClub downgraded shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Finally, HSBC Holdings plc downgraded shares of Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday, May 19th. One analyst has rated the stock with a sell rating, nine have given a hold rating and fifteen have assigned a buy rating to the stock. Shire PLC presently has an average rating of “Buy” and a consensus price target of $220.08.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.